XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Organization and Liquidity - Additional information (Details)
$ / shares in Units, $ in Thousands
6 Months Ended 9 Months Ended
Sep. 19, 2023
USD ($)
$ / shares
shares
Jun. 30, 2024
USD ($)
Program
Sep. 30, 2023
Dec. 31, 2023
USD ($)
Sep. 20, 2023
shares
Jun. 30, 2023
USD ($)
Organization and Liquidity [Line items]            
Number of clinical and preclinical neuroscience programs | Program   7        
Reverse stock split   7.8463-for-1        
Reverse stock split conversion ratio     0.1274      
Preferred stock, shares authorized | shares         50,000,000  
Accumulated deficit   $ (815,855)   $ (703,434)    
Cash and cash equivalents   150,678   374,038   $ 204,218
Marketable securities   220,961   $ 79,944    
Initial Public Offering            
Organization and Liquidity [Line items]            
Common stock sold in initial public offering | shares 14,710,000          
Price to public, per share | $ / shares $ 17          
Proceeds from initial public offering $ 226,500          
Underwriting discounts and commissions 17,500          
Offering expenses $ 6,000          
Common stock shares authorized | shares 700,000,000          
Common stock, par value | $ / shares $ 0.0001          
Preferred stock, shares authorized | shares 50,000,000          
Preferred stock, par value | $ / shares $ 0.0001          
Number of convertible preferred stock automatically converted into shares of common stock | shares 104,417,415          
Liquidity            
Organization and Liquidity [Line items]            
Accumulated deficit   815,900        
Cash, cash equivalents, and marketable securities   $ 371,600